BRPI0908889A2 - polipeptídeo omci ou polinucleotídeo que codifica o mesmo, método para tratar ou prevenir uma doença ou condição mediada por um leucotrieno ou hidroxieicosanóide em um paciente, e, composição - Google Patents

polipeptídeo omci ou polinucleotídeo que codifica o mesmo, método para tratar ou prevenir uma doença ou condição mediada por um leucotrieno ou hidroxieicosanóide em um paciente, e, composição

Info

Publication number: BRPI0908889A2
Authority: BR; Brazil
Prior art keywords: hydroxyeicosanoid; leukotriene; patient; treating; preventing
Prior art date: 2008-02-05

Application number

BRPI0908889A

Other languages

English (en)

Inventor

Miles Nunn

Pietro Roversi

Susan Lea

Original Assignee

Natural Environment Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-05

Filing date

2009-02-05

Publication date

2015-09-15

2009-02-05 Application filed by Natural Environment Res filed Critical Natural Environment Res

2015-09-15 Publication of BRPI0908889A2 publication Critical patent/BRPI0908889A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI0908889A 2008-02-05 2009-02-05 polipeptídeo omci ou polinucleotídeo que codifica o mesmo, método para tratar ou prevenir uma doença ou condição mediada por um leucotrieno ou hidroxieicosanóide em um paciente, e, composição BRPI0908889A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0802116.4A GB0802116D0 (en)	2008-02-05	2008-02-05	Treatment
PCT/GB2009/000311 WO2009098454A2 (en)	2008-02-05	2009-02-05	Treatment of diseases and conditions mediated by eicosanoids

Publications (1)

Publication Number	Publication Date
BRPI0908889A2 true BRPI0908889A2 (pt)	2015-09-15

Family

ID=39204277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0908889A BRPI0908889A2 (pt)	2008-02-05	2009-02-05	polipeptídeo omci ou polinucleotídeo que codifica o mesmo, método para tratar ou prevenir uma doença ou condição mediada por um leucotrieno ou hidroxieicosanóide em um paciente, e, composição

Country Status (10)

Country	Link
US (1)	US20110059885A1 (pt)
EP (1)	EP2254667A2 (pt)
JP (1)	JP2011511632A (pt)
CN (1)	CN102066412A (pt)
AU (1)	AU2009211257A1 (pt)
BR (1)	BRPI0908889A2 (pt)
CA (1)	CA2713032A1 (pt)
GB (1)	GB0802116D0 (pt)
MX (1)	MX2010008353A (pt)
WO (1)	WO2009098454A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0518443D0 (en)	2005-09-09	2005-10-19	Evolutec Ltd	Method of treating myasthenia gravis
GB0906779D0 (en) *	2009-04-20	2009-06-03	Natural Environment Res Council	Composition
GB0907413D0 (en)	2009-04-29	2009-06-10	Equateq Ltd	Novel methods
CA2785612C (en) *	2010-01-08	2019-09-10	Varleigh Immuno Pharmaceuticals (Vip) Ltd.	Ev576 for use in the treatment of viral infections of the respiratory tract
US8293790B2 (en)	2011-10-19	2012-10-23	Dignity Sciences Limited	Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2014022816A2 (en) *	2012-08-03	2014-02-06	Dignity Sciences Limited	Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201301626D0 (en)	2013-01-30	2013-03-13	Dignity Sciences Ltd	Composition comprising 15-OHEPA and methods of using the same
GB201307082D0 (en) *	2013-04-19	2013-05-29	Dignity Sciences Ltd	Pharmaceutical composition comprising 15-HETrE and methods of using the same
ES2727387T3 (es)	2013-11-15	2019-10-15	Ds Biopharma Ltd	Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
PT3097076T (pt) *	2014-01-22	2019-07-30	Max Delbrueck Centrum Fuer Molekulare Medizin	Novos derivados cyp-eicosanoides
GB201410116D0 (en)	2014-06-06	2014-07-23	Volution Immuno Pharmaceuticals Sa	Method of treatment
MA41120A (fr) *	2014-12-02	2017-10-10	Afimmune Ltd	Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US9873878B2 (en) *	2015-03-30	2018-01-23	University Of Louisville Research Foundation, Inc.	Compositions and methods for use in treating silicosis and lung cancer
CN112245420A (zh) *	2015-07-21	2021-01-22	艾菲穆恩有限公司	用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
AU2016370626B2 (en)	2015-12-18	2020-08-20	Afimmune Limited	Compositions comprising 15-HEPE and methods of using the same
GB201602802D0 (en)	2016-02-17	2016-03-30	Volution Immuno Pharmaceuticals Sa	Method of treatment
JP7209637B2 (ja)	2017-04-21	2023-01-20	ヴォリューションイミュノファーマシューティカルズエスエイ	自己免疫性水疱症の治療のためのコバーシン
GB201706406D0 (en) *	2017-04-21	2017-06-07	Volution Immuno Pharmaceuticals Sa	Method of treatment
CN110831617A (zh) *	2017-04-21	2020-02-21	沃卢申伊缪诺制药公司	用于治疗瘢痕性眼部发炎性病症的Coversin
JP7629394B2 (ja) *	2018-09-10	2025-02-13	ヴォリューションイミュノファーマシューティカルズエスエイ	リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) *	2019-04-25	2019-06-05	Volution Immuno Pharmaceuticals Sa	Method of treatment
US20210315851A1 (en)	2020-04-03	2021-10-14	Afimmune Limited	Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN113049802B (zh) *	2021-03-23	2022-10-14	广州医科大学附属第一医院（广州呼吸中心）	一种用于评估变应原特异性免疫治疗效果的血清学标志物
CN120539404B (zh) *	2025-05-23	2026-04-14	北京医院	一种辅助诊断系统性红斑狼疮的生物标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5650435A (en) *	1991-04-01	1997-07-22	Madara; James L.	Modulation of inflammation related to columnar epithelia
CA2465117C (en) *	2001-11-06	2012-01-03	Brigham And Women's Hospital, Inc.	Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
WO2003105831A1 (en) *	2002-06-14	2003-12-24	Alcon, Inc.	Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
US7884188B2 (en) *	2003-06-02	2011-02-08	Varleigh Immuno Pharmaceuticals (Vip) Ltd	Complement inhibitors
GB0518443D0 (en) *	2005-09-09	2005-10-19	Evolutec Ltd	Method of treating myasthenia gravis
EP2012828A2 (en) *	2006-04-28	2009-01-14	Resolvyx Pharmaceuticals, Inc.	Compositions and methods for the treatment of cardiovascular disease
EP2061501B1 (en) *	2006-09-08	2015-04-08	Volution Immuno Pharmaceuticals SA	Method of treating respiratory disorders

2008
- 2008-02-05 GB GBGB0802116.4A patent/GB0802116D0/en not_active Ceased
2009
- 2009-02-05 BR BRPI0908889A patent/BRPI0908889A2/pt not_active IP Right Cessation
- 2009-02-05 WO PCT/GB2009/000311 patent/WO2009098454A2/en not_active Ceased
- 2009-02-05 CN CN2009801040319A patent/CN102066412A/zh active Pending
- 2009-02-05 CA CA2713032A patent/CA2713032A1/en not_active Abandoned
- 2009-02-05 JP JP2010544785A patent/JP2011511632A/ja not_active Withdrawn
- 2009-02-05 AU AU2009211257A patent/AU2009211257A1/en not_active Abandoned
- 2009-02-05 MX MX2010008353A patent/MX2010008353A/es not_active Application Discontinuation
- 2009-02-05 US US12/866,024 patent/US20110059885A1/en not_active Abandoned
- 2009-02-05 EP EP09709173A patent/EP2254667A2/en not_active Withdrawn

Also Published As

Publication number	Publication date
CN102066412A (zh)	2011-05-18
MX2010008353A (es)	2010-11-09
WO2009098454A3 (en)	2010-06-24
GB0802116D0 (en)	2008-03-12
CA2713032A1 (en)	2009-08-13
US20110059885A1 (en)	2011-03-10
EP2254667A2 (en)	2010-12-01
AU2009211257A1 (en)	2009-08-13
WO2009098454A2 (en)	2009-08-13
JP2011511632A (ja)	2011-04-14

Legal Events

Date	Code	Title	Description
2015-12-08	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0921317A2 (pt)	2017-06-06	composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BR112012004333A2 (pt)	2015-09-08	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0908503A2 (pt)	2015-09-29	partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI1008974A2 (pt)	2017-06-06	composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
BRPI0717753A2 (pt)	2013-10-22	Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição.
BRPI0916576A2 (pt)	2017-06-27	pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
BR112015003332A2 (pt)	2017-09-26	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt)	2018-04-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI1014824A2 (pt)	2018-07-24	composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo
BRPI1013705A2 (pt)	2016-04-05	compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI1006145A2 (pt)	2017-05-30	"composição e método para tratamento de diabetes".
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0915986A2 (pt)	2015-11-03	composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo
BRPI0810144A2 (pt)	2014-10-14	Método para aumentar saúde das plantas e/ou controlar pestes em plantas
BRPI0816097A2 (pt)	2016-11-01	composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0907162A2 (pt)	2015-07-07	Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
BRPI0816814A2 (pt)	2017-05-16	composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.
BRPI0917257A2 (pt)	2015-11-10	sistema, e método para liberar um componente em uma zona de um poço ou próxima a um poço
FI20070935A0 (fi)	2007-12-03	Koostumus ja menetelmä puun käsittelemiseksi
BRPI1000030A2 (pt)	2018-02-14	métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
BR112012002001A2 (pt)	2016-05-10	método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit